Interpretation and Optimization of Nutrition in the Intensive Care Units
Launched by DIM3 · Mar 26, 2024
Trial Information
Current as of June 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to improve nutrition for patients in intensive care units (ICUs). Many ICU patients don't get enough calories and protein, which can lead to serious problems like infections and longer recovery times. The trial is testing a new software called Nutrow®, which helps healthcare providers keep track of how much nutrition patients are supposed to receive and how much they actually get. By using Nutrow® along with another device called Feedim®, researchers hope to make sure that ICU patients receive the right amount of nutrition before they can eat normally again.
To participate in this study, patients must be at least 18 years old and registered with the French Social Security system. They should be in the ICU for the first time, have been there for at least three days, and be receiving nutritional support. Before joining, patients or their family members will be fully informed about the study and must give their consent. Participants can expect to receive close monitoring of their nutritional intake and support from the research team throughout the study. This trial aims to improve patient care and recovery by ensuring that nutritional needs are met effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 and over.
- • French Social Security system registration.
- • First stay in ICU
- • Admitted to the Lille University Hospital Surgical ICU for at least 3 days.
- • Active enteral and/or parenteral nutritional support prescription
- • Patient and/or next-of-kin informed about the study and having consented to participation in the study.
- Exclusion Criteria:
- • Age under 18
- • Burn patient
- • Admitted to the ICU with a prior active enteral/parenteral nutritional support before day 3, except trophic nutrition
- • Dying patient, not-to-be-resuscitated order, or other treatment limitation decision at ICU admission
- • Adult under guardianship
- • Department of corrections inmate
About Dim3
dim3 is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on enhancing patient outcomes, dim3 specializes in conducting robust clinical trials across various therapeutic areas. The organization is committed to adhering to the highest ethical standards and regulatory compliance, ensuring the integrity of its studies. By leveraging cutting-edge technology and a collaborative approach, dim3 aims to streamline the clinical trial process, making it more efficient and accessible for patients and healthcare providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lille, , France
Patients applied
Trial Officials
Eric KIPNIS, MD,PhD
Principal Investigator
University Hospital, Lille
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported